Skip to Main Content

Paper Details

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
0
2023
Iscalimab, MG, Patients, anti-CD40 monoclonal antibody, human, iscalimab, myasthenia gravis, patients
Author NameAffiliation
Ronenn RoubenoffNovartis Institutes for BioMedical Research
  • 1 - 1

Datasets

Release 1.2